Literature DB >> 11297261

Photodynamic therapy in the canine prostate using motexafin lutetium.

R A Hsi1, A Kapatkin, J Strandberg, T Zhu, T Vulcan, M Solonenko, C Rodriguez, J Chang, M Saunders, N Mason, S Hahn.   

Abstract

Our purpose was to determine the feasibility of comprehensive treatment of the canine prostate with photodynamic therapy (PDT) using motexafin lutetium (Lu-Tex) and to evaluate the toxicity and tissue effects associated with this treatment. Twenty-five adult male beagles with normal prostate glands were given an i.v. injection of the second-generation photosensitizer Lu-Tex (2-6 mg/kg). An additional two dogs were used as controls and did not receive any photosensitizing drug. All 27 dogs underwent laparotomy to expose the prostate. Three hours postinjection, a total dose of 75-150 J/cm of 732 nm laser light was delivered interstitially and/or transurethrally to the prostate via cylindrical diffusing fibers. Dogs were euthanized between 2 days and 3 months after PDT. All subjects were monitored for clinical evidence of toxicity. Specimens were examined macroscopically and microscopically to characterize the tissue reaction and assess extent of tissue effect as a result of treatment. Interstitial and/or transurethral PDT were successfully delivered in all dogs with no perioperative complications. No clinical evidence of acute urinary obstruction or rectal bleeding was noted. At all dose levels, macroscopic and microscopic evaluation revealed a prostatic tissue reaction characterized initially (within 48 h) by inflammation and necrosis followed by fibrosis and glandular epithelial atrophy. Comprehensive treatment of the entire prostate could be achieved using the interstitial alone approach or combined transurethral and interstitial approach. The transurethral alone approach did not result in complete coverage of the prostate. Dogs receiving transurethral or combined interstitial and transurethral treatment developed erythema and urethral epithelial disruption at all dose levels. Those receiving combined treatment at the highest dose level (Lu-Tex 6 mg/kg, 150 J/cm light) developed urethral fistulae and peritonitis. Dogs treated with the interstitial alone approach were found to have the least amount of urethral damage. Comprehensive treatment of the canine prostate with Lu-Tex PDT is feasible using an interstitial alone or combined interstitial and transurethral approach. The interstitial alone technique results in the least amount of toxicity. The prostatic tissue reaction to treatment is characterized by initial inflammation and necrosis followed by fibrosis and glandular epithelial atrophy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11297261

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  21 in total

1.  Effects of Pd-bacteriopheophorbide (TOOKAD)-mediated photodynamic therapy on canine prostate pretreated with ionizing radiation.

Authors:  Zheng Huang; Qun Chen; Nadira Trncic; Susan M LaRue; Pierre-Hervé Brun; Brian C Wilson; Howard Shapiro; Fred W Hetzel
Journal:  Radiat Res       Date:  2004-06       Impact factor: 2.841

Review 2.  Photodynamic therapy for focal ablation of the prostate.

Authors:  Nimalan Arumainayagam; C M Moore; Hashim U Ahmed; M Emberton
Journal:  World J Urol       Date:  2010-05-09       Impact factor: 4.226

3.  Effects of photodynamic therapy on peripheral nerve: in situ compound-action potentials study in a canine model.

Authors:  Kenneth C Dole; Qun Chen; Fred W Hetzel; Lawrence R Whalen; Dominique Blanc; Zhen Huang
Journal:  Photomed Laser Surg       Date:  2005-04       Impact factor: 2.796

4.  The effect of Tookad-mediated photodynamic ablation of the prostate gland on adjacent tissues--in vivo study in a canine model.

Authors:  Zheng Huang; Qun Chen; Kenneth C Dole; Al B Barqawi; Yang K Chen; Dominique Blanc; Brian C Wilson; Fred W Hetzel
Journal:  Photochem Photobiol Sci       Date:  2007-08-22       Impact factor: 3.982

5.  Treatment planning using tailored and standard cylindrical light diffusers for photodynamic therapy of the prostate.

Authors:  Augusto Rendon; J Christopher Beck; Lothar Lilge
Journal:  Phys Med Biol       Date:  2008-02-05       Impact factor: 3.609

Review 6.  Photodynamic therapy for prostate cancer--a review of current status and future promise.

Authors:  Caroline M Moore; Doug Pendse; Mark Emberton
Journal:  Nat Clin Pract Urol       Date:  2009-01

7.  Interstitial fluorescence spectroscopy in the human prostate during motexafin lutetium-mediated photodynamic therapy.

Authors:  Jarod C Finlay; Timothy C Zhu; Andreea Dimofte; Diana Stripp; S Bruce Malkowicz; Theresa M Busch; Stephen M Hahn
Journal:  Photochem Photobiol       Date:  2006 Sep-Oct       Impact factor: 3.421

8.  Prostate PDT dosimetry.

Authors:  Timothy C Zhu; Jarod C Finlay
Journal:  Photodiagnosis Photodyn Ther       Date:  2006-10-19       Impact factor: 3.631

9.  Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen.

Authors:  Hiral Patel; Rosemarie Mick; Jarod Finlay; Timothy C Zhu; Elizabeth Rickter; Keith A Cengel; S Bruce Malkowicz; Stephen M Hahn; Theresa M Busch
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

10.  High-field magnetic resonance imaging of the response of human prostate cancer to Pc 4-based photodynamic therapy in an animal model.

Authors:  Baowei Fei; Hesheng Wang; Joseph D Meyers; Denise K Feyes; Nancy L Oleinick; Jeffrey L Duerk
Journal:  Lasers Surg Med       Date:  2007-10       Impact factor: 4.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.